Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mookerjee

Showing results (401-410 of 461) with videos related to

Pageof 47
Sort By:
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Scientific Reports|October 7, 2017
Emergence and clonal spread of colistin resistance due to multiple mutational mechanisms in carbapenemase-producing Klebsiella pneumoniae in LondonJonathan A Otter, Michel Doumith, Frances Davies, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2020
Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant OrganismsRohma Ghani, Benjamin H Mullish, Julie A K McDonald, et al.
Journal of Primary Care & Community Health|July 28, 2025
Risk Factors and Comorbidities Associated With Vitamin B<sub>12</sub> Deficiency in an Adult PopulationAlexandra Lane, Lucinda Lau, Christy Alhannat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal of Hepatology|March 29, 2003
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitisHerbert Tilg, Rajiv Jalan, Arthur Kaser, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver DiseaseFrancesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Journal of Hepatology|June 21, 2020
Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleedingRahul Kumar, Annarein J C Kerbert, M Faisal Sheikh, et al.
Pageof 47

Showing results (401-410 of 461) with videos related to

Sort By:
Pageof 47
Nature Medicine|June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Scientific Reports|October 7, 2017
Emergence and clonal spread of colistin resistance due to multiple mutational mechanisms in carbapenemase-producing Klebsiella pneumoniae in LondonJonathan A Otter, Michel Doumith, Frances Davies, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2020
Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant OrganismsRohma Ghani, Benjamin H Mullish, Julie A K McDonald, et al.
Journal of Primary Care & Community Health|July 28, 2025
Risk Factors and Comorbidities Associated With Vitamin B<sub>12</sub> Deficiency in an Adult PopulationAlexandra Lane, Lucinda Lau, Christy Alhannat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Journal of Hepatology|March 29, 2003
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitisHerbert Tilg, Rajiv Jalan, Arthur Kaser, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Hepatology (Baltimore, Md.)|August 6, 2019
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver DiseaseFrancesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
Journal of Hepatology|June 21, 2020
Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleedingRahul Kumar, Annarein J C Kerbert, M Faisal Sheikh, et al.
Pageof 47